However, the 7 patients with hormone receptor–positive disease and PGVs received a diagnosis between 29 and 45 years of age, and those who received a diagnosis at older than 50 years had triple-negative breast cancer; therefore, these individuals would have been captured for germline testing eligibility by current guidelines. Here, NR4A1 is linked to triple-negative breast carcinoma.